{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:56:54Z","timestamp":1767905814268,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.rmed.2025.108112","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:01:19Z","timestamp":1745323279000},"page":"108112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension"],"prefix":"10.1016","volume":"243","author":[{"given":"Carly J.","family":"Paoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7963-8406","authenticated-orcid":false,"given":"Chang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-692X","authenticated-orcid":false,"given":"Xiaoqin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-8510","authenticated-orcid":false,"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6519-0111","authenticated-orcid":false,"given":"Abbey","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1285-3628","authenticated-orcid":false,"given":"Karim","family":"El-Kersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2025.108112_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108112_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"38","key":"10.1016\/j.rmed.2025.108112_bib3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108112_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","article-title":"Pulmonary vascular remodeling in pulmonary hypertension","volume":"367","author":"Tuder","year":"2017","journal-title":"Cell Tissue Res."},{"issue":"12","key":"10.1016\/j.rmed.2025.108112_bib6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.rmed.2025.108112_bib7","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.rmed.2025.108112_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108112_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108112_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","author":"Chin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108112_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618823440","article-title":"Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience","volume":"13","author":"Belge","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108112_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FJC.0000000000000283","article-title":"Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA versus ETB receptors and on the functionality of endothelial ETB receptors","volume":"66","author":"Iglarz","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108112_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020954158","article-title":"Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis","volume":"10","author":"Benza","year":"2020","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.rmed.2025.108112_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s41030-023-00244-w","article-title":"Comparative treatment persistence and adherence to endothelin receptor antagonists among patients with pulmonary arterial hypertension in Japan: a real-world administrative claims database study","volume":"9","author":"Omura","year":"2023","journal-title":"Pulm Ther"},{"key":"10.1016\/j.rmed.2025.108112_bib17","series-title":"Persistence with Macitentan versus Ambrisentan and Bosentan in Patients with Pulmonary Arterial Hypertension: Experience from a Real-World Data Repository in the USA","author":"Paoli","year":"2022"},{"issue":"5","key":"10.1016\/j.rmed.2025.108112_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1378\/chest.14-0193","article-title":"Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry","volume":"146","author":"Burger","year":"2014","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2025.108112_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.12-3023","article-title":"Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis","volume":"144","author":"Frost","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2025.108112_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11906-019-0950-y","article-title":"The use of risk assessment tools and prognostic scores in managing patients with pulmonary arterial hypertension","volume":"21","author":"Kanwar","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"issue":"4","key":"10.1016\/j.rmed.2025.108112_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chest.2019.10.043","article-title":"Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents","volume":"157","author":"McLaughlin","year":"2020","journal-title":"Chest"},{"issue":"8 Suppl","key":"10.1016\/j.rmed.2025.108112_bib22","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108112_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"issue":"5","key":"10.1016\/j.rmed.2025.108112_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3111\/13696998.2012.690801","article-title":"Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States","volume":"15","author":"Copher","year":"2012","journal-title":"J. Med. Econ."},{"issue":"1 Suppl","key":"10.1016\/j.rmed.2025.108112_bib25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2009.04.013","article-title":"The 4th world Symposium on pulmonary hypertension. Introduction","volume":"54","author":"Humbert","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.rmed.2025.108112_bib26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.healun.2013.08.010","article-title":"Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry","volume":"32","author":"Farber","year":"2013","journal-title":"J. Heart Lung Transplant."},{"issue":"3","key":"10.1016\/j.rmed.2025.108112_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1378\/chest.15-1051","article-title":"Parenteral prostanoid use at a tertiary referral center: a retrospective cohort study","volume":"149","author":"Hay","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2025.108112_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/rccm.201209-1640OC","article-title":"Causes and circumstances of death in pulmonary arterial hypertension","volume":"188","author":"Tonelli","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108112_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","article-title":"Effect of macitentan on hospitalizations: results from the SERAPHIN trial","volume":"3","author":"Channick","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.rmed.2025.108112_bib30","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2017.12.010","article-title":"Pulmonary arterial hypertension-related morbidity is prognostic for mortality","volume":"71","author":"McLaughlin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"26","key":"10.1016\/j.rmed.2025.108112_bib31","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108112_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018816294","article-title":"3rd. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database","volume":"9","author":"Studer","year":"2019","journal-title":"Pulm. Circ."},{"issue":"2","key":"10.1016\/j.rmed.2025.108112_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12090","article-title":"Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States","volume":"12","author":"Pizzicato","year":"2022","journal-title":"Pulm. Circ."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500174X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500174X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:25:46Z","timestamp":1762039546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112500174X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"alternative-id":["S095461112500174X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108112","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108112"}}